Clinical value of interleukin - 6 as a potential biomarker for bronchogenic carcinoma: A clinical study

Abstract

Background: Bronchogenic carcinoma, a predominant form of lung cancer, continues to challenge diagnostic modalities with its late detection and poor prognosis. Interleukin-6 (IL6), a cytokine involved in inflammatory and immune responses, has recently been scrutinized for its potential role as a biomarker in various cancers. This clinical study evaluates the clinical value of IL-6 levels in patients with bronchogenic carcinoma, aiming to establish its utility in early diagnosis and prognosis estimation.